Inventors with similar research interests:
Location History:
- New York, NY (US) (1991 - 2005)
- Teaneck, NJ (US) (1999 - 2006)
Company Filing History:
49 out of 126 
4 out of 507 
2 out of 2 Years Active: 1991-2006
Areas of Expertise:
Title: Richard L Weinshank: A Proficient Innovator in Galanin Receptors
Introduction:
Richard L Weinshank, an inventive mind in New York, NY, has made significant contributions in the field of galanin receptors. With a total of 56 patents to his name, Weinshank's dedication and expertise have opened new avenues in the understanding and utilization of galanin receptor proteins. In this article, we will explore his latest patents, career highlights, and collaborations that have marked his journey as an accomplished innovator.
Latest Patents:
Weinshank's recent patents highlight his pioneering work in isolating nucleic acids encoding mammalian galanin receptors, along with a range of related applications. These patents include the following inventions:
1. Uses of galanin GALR2 receptors:
This invention encompasses isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acids, cells containing such vectors, antibodies targeting mammalian galanin receptors, nucleic acid probes for detection, antisense oligonucleotides, and nonhuman transgenic animals expressing DNA encoding normal or mutant galanin receptors. It also encompasses methods for determining the binding of compounds to mammalian galanin receptors.
2. Method of preparing GALR2 receptors composition:
Similar to the first patent, this invention focuses on isolated nucleic acids encoding mammalian galanin receptors, isolated receptor proteins, vectors containing these nucleic acids, cells carrying such vectors, antibodies directed towards mammalian galanin receptors, nucleic acid probes for detection, antisense oligonucleotides, and nonhuman transgenic animals expressing DNA encoding normal or mutant galanin receptors. It also involves methods for evaluating the binding affinity of compounds to mammalian galanin receptors.
Career Highlights:
Weinshank's career has been marked by his invaluable contributions to advancing the field of galanin receptors. Notably, he has worked with renowned companies such as Synaptic Pharmaceutical Corporation and H. Lundbeck A/S. These collaborations have allowed him to leverage his inventive skills and work alongside industry experts to develop breakthrough solutions.
Collaborations:
Throughout his career, Richard L Weinshank has collaborated with accomplished professionals in the field, including Theresa A Branchek and Paul R Hartig. Their combined expertise and dedication have propelled the development and application of galanin receptor technologies, pushing the boundaries of scientific understanding and potential therapeutic interventions.
Conclusion:
Richard L Weinshank's impressive portfolio of patents demonstrates his exceptional aptitude for innovation in galanin receptors. His patents have paved the way for new discoveries, promising novel therapeutic prospects and facilitating further research in this field. Through his collaborations and industry experience, Weinshank has reinforced his standing as a driving force behind advancements in the understanding and utilization of galanin receptors.